参芪扶心口服液对心力衰竭大鼠血浆利钾尿肽、左室舒缩性能及左室重塑的影响

目的:观察参芪扶心口服液对实验性心力衰竭(心衰)大鼠血浆利钾尿肽(KP)、左室舒缩功能及左室重塑的影响。方法:采用缩窄腹主动脉方法复制大鼠心衰模型。左心室插管术测定血液动力学指标;放免法测定血浆KP,心钠素(ANP),血管紧张素Ⅱ(Ang Ⅱ)及内皮素(ET)浓度,并观察心脏形态学结构及胶原成分、心脏湿重/体重、左心腔面积、单位面积内心肌细胞核数的变化。结果:与假手术组相比,模型组血浆KP,ANP,Ang Ⅱ及ET水平显著升高,心脏湿重/体重、左心腔面积增加、单位面积内心肌细胞核数减少(P<0.01)。与模型组相比,参芪扶心口服液高剂量组等容收缩末期心肌缩短最大速度(Vmax)、左心室舒张期压力下降最大变化速率(-dp/dtmax)及左心室内压峰值(LVSP)增加,左心室舒张末压(LVEDP)降低,血浆KP,Ang Ⅱ及ET浓度降低,均有显著性差异(P<0.05或P<0.01);血浆ANP、左心室等容收缩期压力最大变化速率(+dp/dtmax)下降不明显(P>0.05);心肌细胞周围胶原组织明显减少,心脏湿重/体重比值变小、单位面积内心肌细胞核数明显增多、左心腔面积明显缩小(P<0.05或P<0.01)。参芪扶心口服液各剂量组及卡托普利组对+dp/dtmax的影响均不显著(P>0.05)。参芪扶心口服液中、低剂量组血浆ANP水平下降明显(P<0.01)。结论:参芪扶心口服液能改善心衰大鼠左室舒缩功能，降低KP，AngⅡ，ET浓度，影响ANP分泌，有一定抑制左室重塑的作用。

Effects of Shenqifuxin Oral Liquid on the Plasma Kaliuretic Peptide, the Myocardial Contractility and Relaxation of Left Ventricle and the Left Ventricular Remodeling in Experimental Rats with Heart Failure

OBJECTIVE: To observe the effects of Shenqifuxin oral liquid(SQFXOL) on plasma kaliuretic peptide (KP), atrial natriuretic polypeptide(ANP), angiotension II (Ang II), endothelin(ET) and the left ventricular remodeling and the myocardial contractility and relaxation of left ventricle in experimental rats with heart failure(HF). METHOD: The SD rat model with HF was produced by constricting abdominal aorta. Hemodynamic parameters including maximum rate of intraventricular pressure rise (+dp/dtmax), left ventricular systolic pressure(LVSP), maximum velocity of contractile element shortening(Vmax), maximum rate of intraventricular pressure down(-dp/dtmax) and left ventricular end diastolic pressure(LVEDP) were measured by the method of the catheterization. Plasma concentrations of KP, ANP, Ang II and ET were determined by radioimmunoassays. The effects of treatment were evaluated by observing and comparing the changes of heart morphological structure, collagen element, heart weight/body weight ratio (HW/BW), left intraventricular area(LVA) and myocardial nuclei number (MNN) per square area. RESULT: In high dose SQFXOL group, the LVSP, -dp/dtmax and Vmax were increased, while LVEDP was decreased, and plasma concentrations of KP, Ang II and ET were decreased. In comparision with those in model group, the difference was significant(P < 0.05 or P < 0.01). Though the +dp/dtmax and the level of ANP were decreased, the difference was insignificant(all P > 0.05). The collagen tissues around myocardial cells were reduced. HW/BW and LVA were lower, and MNN per square area was higher significantly (P < 0.05 or P < 0.01). The indices of +dp/dtmax in all of treatment groups and control group were not considerably different in comparison with those in model group. The levels of plasma ANP in middle dose group and low dose group were significantly lower than those in model group(all P < 0.01). CONCLUSION: SQFXOL can reduce the plasma concentrations of KP, Ang II, ET, and ANP, improve the myocardial contractility and relaxation of left ventricular and inhibitate left ventricular remodeling in rats with HF.